The Fluctuation Trend of Serum Anti-SARS-CoV-2 IgM/IgG Antibodies Seroprevalence in the Non-COVID-19 Infected Population and Correlation with Peripheral Blood Leukocyte Parameters in Beijing, China, 2021: A Real-World Study

Wang, Pan; Yang, Nan; Xue, Yuting; Zhou, Jiaolin; Wu, Yonghua; Wang, Tiancheng; Cui, Lianxian

doi:10.3390/vaccines10040571

Cited by 2 publications

(1 citation statement)

References 29 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of a previous clinical trial showed that immunogenicity was comparatively lower in older as compared to younger individuals after receiving the COVID-19 BNT162b2 vaccination, as evidenced by the Ab response [30]. In another study [31], the overall immune response was limited in individuals aged > 55 years following two doses of the inactivated CoronaVac vaccine. Intriguingly, a clinical The effect of the proportion of lymphocytes on the responses of Abs against RBD-IgG remains unclear, as two past studies found positive correlations between the responses of Abs against RBD-IgG and lymphocyte counts [35,36], while another found no relationship [37].…”

Section: Discussionmentioning

confidence: 96%

The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients

Yang

Feng

Wang

et al. 2023

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

The immunogenicity and safety of vaccines against coronavirus disease 2019 (COVID-19) remain unknown in patients with a history of pulmonary tuberculosis (OPTB). Therefore, the safety and effectiveness of inactivated vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) were assessed in patients with a history of PTB. The study cohort included 106 healthy controls and 93 adult patients with OPTB who received a two-dose vaccination. The study period was 21 to 105 days. Concentrations of antibodies (Abs) against receptor-binding domain (RBD) IgG and SARS-CoV-2 neutralizing Abs (NAbs) were measured, in addition to the frequencies of SARS-CoV-2-specific B and a portion T cells. The incidence of adverse events was similar between the OPTB patients and healthy controls. No severe adverse events occurred. Concentrations of Abs against RBD-IgG and CoV-2 neutralizing Abs in addition to the frequencies of RBD-specific memory B cells proportions were lower in OPTB patients than the healthy controls (all, p < 0.05), while the frequencies of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4 + ) cells were higher ( p = 0.023). There was no obvious correlation between age and blood concentrations of Abs against RBD-IgG and CoV-2 neutralizing Abs, while immune responses were similar in the fibrosis and calcification groups. The period of time following full-course vaccination and lymphocyte counts were associated to anti-RBD-IgG responses. Inactivated COVID-19 vaccinations were well tolerated in OPTB patients, although immunogenicity was limited in this population. This study has been registered at ClinicalTrials.gov (NCT05043246). Supplementary Information The online version contains supplementary material available at 10.1007/s10096-023-04566-0.

show abstract

Section: Discussionmentioning

confidence: 96%

The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients

Yang

Feng

Wang

et al. 2023

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

show abstract

Seroepidemiology of SARS-CoV-2 antibody and infection rate estimation following a high-intensity epidemic of COVID-19 in Guangdong Province, China: A large population cross-sectional investigation (Preprint)

2023

Preprint

View full text Add to dashboard Cite

BACKGROUND Background: Along with the epidemic response policy adjustment in China, a surge in COVID-19 infection occurred between December 2022 and January 2023. However, the exact proportion of individuals infected during this period remains uncertain. METHODS Methods: A population-level seroepidemiology study was conducted from February to April 2023 in Guangdong Province. The questionnaire and venous blood samples were collected from participants and IgG antibodies against SARS-CoV-2 in serum samples were tested. The chi-square test was used to analyze differences in IgG seroprevalence among participants with different characteristics, and multivariate linear regression was performed to examine the factors affecting IgG levels. Based on a pre-survey cutoff for IgG levels, infection rates (%) for the population were estimated by characteristics. RESULTS Results: Among the total of 10,747 participants, 10,368 (96.47%, 95%CI: 96.12%-96.82%) were seropositive for SARS-CoV-2 IgG, and the median IgG was 82 (IQR:47-108) S/CO. Seroprevalence and IgG level was lower in the young, the elderly, and participants with chronic diseases. Multiple linear regression analysis revealed significant associations between IgG level and age group, gender, self-reported infection, and latest vaccination time. The infection rate of SARS-CoV-2 in the whole population in Guangdong Province was estimated to be 85.53% following the COVID-19 high-intensity epidemic, corresponding to 107.8 million population were infected. CONCLUSIONS Conclusions: The seropositive for SARS-CoV-2 IgG and the estimated natural infection rate of SARS-CoV-2 in this outbreak in Guangdong province was at a relatively high level. The young and the elderly are vulnerable populations that need to be focused on and protected.

show abstract

The Fluctuation Trend of Serum Anti-SARS-CoV-2 IgM/IgG Antibodies Seroprevalence in the Non-COVID-19 Infected Population and Correlation with Peripheral Blood Leukocyte Parameters in Beijing, China, 2021: A Real-World Study

Cited by 2 publications

References 29 publications

The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients

The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients

Seroepidemiology of SARS-CoV-2 antibody and infection rate estimation following a high-intensity epidemic of COVID-19 in Guangdong Province, China: A large population cross-sectional investigation (Preprint)

Contact Info

Product

Resources

About